Rare Biomarkers Specimen Collection And Stabilization Market Research, 2031
The global Rare Biomarkers Specimen Collection And Stabilization Market Size was valued at $23.3 billion in 2021, and is projected to reach $54.2 billion by 2031, growing at a CAGR of 8.7% from 2022 to 2031.A biomarker is a defined characteristic that is measured as an indicator of normal biological processes, pathogenic processes, or responses to an exposure or intervention, including therapeutic interventions. A biomarker can be any biological indicator that can be measured. For instance, biomarkers can be cellular or molecular (DNA, RNA, protein, metabolites). They are measured from a tissue biopsy or a liquid biopsy (blood, urine, saliva). Other biomarkers (physiological, morphological, etc.) can be also used or measured through clinical or medical imaging. It can be either quantitative or qualitative. Qualitative biomarkers could be involved in a pathogenic process detection within a yes/no analysis, while quantitative biomarkers are involved in pathogenic process detection with a threshold effect. The biomarkers are used in research and clinical practice for various purposes, such as for the diagnosis of diseases or predicting risks of disease, monitoring healthy people to detect early signs of disease, determining whether a treatment is efficient or not, targeting specific groups of people for whom a particular drug may be useful, producing safer drugs by predicting the potential for adverse effects earlier and providing researchers with the opportunity of having a global view of the events and changes that are always occurring within a cell.
The key factors that drive Rare Biomarkers Specimen Collection And Stabilization Market Growth are the rise in prevalence of rare and genetic disorders such as cystic fibrosis, muscular dystrophy, spina bifida and various others, increasing preference for minimally non-invasive mode of disease treatment, increasing demand for personalized medicine, and the rise of a geriatric population. For instance, in May, 2022 Illumina, Inc. a global leader in DNA sequencing and array-based technologies, announced the addition of a companion diagnostic (CDx) indication to its CE-marked in vitro diagnostic TruSight Oncology (TSO) comprehensive (EU) test. This single test kit, launched across Europe, assesses multiple tumor genes and biomarkers to reveal the specific molecular profile of a patient's cancer. Moreover, increased R&D activities for the launch of approved novel drugs on rare diseases, favorable government reimbursement policies for rare biomarkers, increased investment in the modern healthcare facility sector, and increased demand for accurate chronic disease diagnosis are anticipated to fuel the market growth.
However, the tedious and lengthy process for the development of biomarker and high cost of the development hampers the market growth. Conversely, emerging healthcare market in developing countries, increase in applications of rare biomarker specimens in pharmacogenomics and increase in the risk of pandemic and rare genetic diseases is expected to provide the lucrative Rare Biomarkers Specimen Collection And Stabilization Market Opportunity during the forecast period.
The rare biomarkers specimen collection and stabilization market is segmented on the basis of type, product, application, and region. By type the market is segmented into circulating cell free DNA, circulating tumor cells and exosomes vesicles. By product the market is segmented into isolation kits & reagents, blood collection tubes and systems. By application, the market is segmented into NIPT, oncology, transcriptomics, pharmacogenomics, transplant rejection, population screening, cardiovascular diseases and other. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA. By application, on the basis of oncology, the market is further sub-segmented into research and diagnostics.
Type Segment review
By type, the rare biomarkers specimen collection and stabilization market is segmented into circulating cell free DNA, circulating tumor cells and exosomes vesicles. In 2021, the circulating cell free DNA segment accounted for the largest share of the market. The dominance of this segment can be attributed tothe increasing adoption of NIPT in detecting chromosomal anomalies in the fetus and as it is a very promising tumor biomarker for cancer diagnosis and monitoring, prognosis assessment, and personalized medication guidance.
The circulating tumor cells segment is anticipated to grow at a significant rate during the forecast period. Owing to recent advancement in circulating tumor cells (CTC) isolation and ex vivo culture techniques facilitate single-cell omics and the development of related animal models to study CTC-mediated metastatic progression which drives the growth of rare biomarkers specimen collection and stabilization market.
Product Segment Review
By product, the market is segmented into isolation kits & reagents, blood collection tubes and systems. In 2021, the isolation kits & reagents segment accounted for the largest Rare Biomarkers Specimen Collection And Stabilization Market Share. The dominance of this segment can be attributed to rise in the prevalence of cancer and rare genetic disorder and the increase in investment for exploring the utility of CTCs in diagnosis, prognosis, and treatment monitoring are the key factors that drives the growth ofthe market in upcoming years.
The blood collection tubes segment are expected to witness considerable market growth during the forecast period, owing to the rise in the geriatric population and the increase in the prevalence of cancer and other chronic diseases which has increased the demand for blood collection tubes for the collection of samples to diagnose lethal and other genetic diseases.
Application Segment Review
By application the rare biomarkers specimen collection and stabilization market is segmented into NIPT, oncology, transcriptomics, pharmacogenomics, transplant rejection, population screening, cardiovascular diseases and others. The oncology segment exhibited the highest growth in 2021, and is anticipated to lead during the forecast period, owing to increase in advancement in technology coupled with an increased interest in personalized medication have led to the rapid expansion of precision medicine in oncology and rise in the prevalence of cancer cases around the globe.
The cardiovascular disease segment is anticipated to grow at a significant rate during the forecast period. Owing to the rise in the prevalence of cardiovascular diseases which increases the demand for the development of novel drug therapies using biomarkers.
Region Segment Review
Region wise, the rare biomarkers specimen collection and stabilization market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America accounted for a majority of the rare biomarker’s specimen collection and stabilization market share in 2021 and is anticipated to remain dominant during the forecast period. The market is mainly driven by the rising prevalence of chronic and genetic diseases, an increase in healthcare expenditure, increase in the number of approved rare biomarker isolation kits for both clinical and research use is anticipated to increase the usage of liquid biopsy and assisted reproductive technology space in the region which drives the Rare Biomarkers Specimen Collection And Stabilization Market Size in the forecast period.
Asia-Pacific was the second largest contributor to the Rare Biomarkers Specimen Collection And Stabilization Industry in 2021, and is expected to register the fastest CAGR during the forecast period. This is due to the presence of high unmet medical needs and constantly improving healthcare infrastructure to cure chronic disorders. In addition, increasing investment for exploring the utility of circulating tumor cells (CTCs) in diagnosis, prognosis, and treatment monitoring has provided lucrative growth opportunities to players involved in the developing marketing will further contribute to the growth of the market.
The key players that operate in the rare biomarkers specimen collection and stabilization market are Agilent Technologies, Bio-Rad Laboratories inc., Charles River Laboratories Inc, F. Hoffman La Roche AG, Merck KGaA, Miltenyi Biotec, Perkin Elmer, Qiagen, Thermofisher Scientific Inc and Siemens AG.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the rare biomarkers specimen collection and stabilization market analysis from 2021 to 2031 to identify the prevailing rare biomarkers specimen collection and stabilization market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the rare biomarkers specimen collection and stabilization market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global rare biomarkers specimen collection and stabilization market trends, key players, market segments, application areas, and market growth strategies.
Rare Biomarkers Specimen Collection and Stabilization Market Report Highlights
| Aspects | Details |
 Market Size By 2031 | USD 54.2 billion |
 Growth Rate | CAGR of 8.7% |
 Forecast period | 2021 - 2031 |
 Report Pages | 356 |
 By Type |
|
 By Product |
|
 By Application |
|
 By Region |
|
 Key Market Players | Siemens Healthineers, Eurofins Scientific, Inc., Qiagen, Thermofischer Scientific Inc, Bio Rad Laboratories, Agilent Technologies Inc, F Hoffman La Roche, Charles River Laboratories International, Inc., Perkin Elmer, Merck Kgaa |
Analyst Review
This section provides various opinions of top-level CXOs in the rare biomarker’s specimen collection and stabilization market. In accordance to several interviews conducted, the rare biomarkers specimen collection and stabilization market is expected to witness a significant growth in the future owing to increase in number of approved rare biomarker isolation kits for clinical and research use is anticipated to increase the usage of liquid biopsy and assisted reproductive technology, and the rise of a geriatric population.
According to the perspectives of CXOs, rare biomarkers specimen collection and stabilization market is expected to witness a steady growth in the future. Rise in geriatric population and growing preference for non-invasive cancer diagnostic are anticipated to fuel the market growth. In addition, surge in investments in R&D by biopharmaceutical companies, the growing healthcare expenditure, increasing investment to explore the utility of circulating tumor cells CTCs in diagnosis, prognosis, and treatment monitoring are the key factors that foster the growth of the market.
However, the lengthy and time taking process of biomarker development and high cost of rare biomarkers are anticipated to hamper the growth of the market up to some extent during the forecast period.
On the contrary, surge in the demand of personalized medicines, increase in the risk of pandemic, and communicable diseases are expected to provide lucrative opportunities for the growth of the rare biomarker’s specimen collection and stabilization market in future.
Further, North America accounted for a majority of the rare biomarker’s specimen collection and stabilization market share in 2021 and is anticipated to remain dominant during the forecast period. The rare biomarkers specimen collection and stabilization market is mainly driven by the rise in prevalence of chronic & genetic diseases, increase in the healthcare expenditure, surge in the number of approved rare biomarker isolation kits for both clinical and research use are anticipated to increase the usage of liquid biopsy and assisted reproductive technology space in the region, which propels the growth of the market.
Asia-Pacific was the second largest contributor to the market in 2021, and is expected to register the fastest CAGR during the forecast period. This is due to the presence of high unmet medical needs and constantly improving healthcare infrastructure to cure chronic disorders. In addition, increasing investment for exploring the utility of circulating tumor cells (CTCs) in diagnosis, prognosis, and treatment monitoring has provided lucrative growth opportunities to players involved in the developing marketing, which further contribute to the growth of the market.
The upcoming trends are are the rise in prevalence of rare and genetic disorders such as cystic fibrosis, muscular dystrophy, spina bifida and various others, increasing preference for minimally non-invasive mode of disease treatment, increasing demand for personalized medicine, and the rise of a geriatric population.
The total market value of rare biomarkers specimen collection and stabilization market is $23,270.04 million in 2021
North America is the Largest Regional Market for Rare Biomarkers Specimen Collection and Stabilization Market.
$54,145.59 million is the Estimated Industry Size of Rare Biomarkers Specimen Collection and Stabilization Market
Agilent Technologies, Bio-Rad Laboratories inc., Charles River Laboratories Inc, F. Hoffman La Roche AG, Merck KGaA are the top Companies to Hold the Market Share in Rare Biomarkers Specimen Collection and Stabilization Market
The forecast period in the report is from 2022 to 2031
The base year for the report is 2021
No, there is value chain analysis provided in the rare biomarkers specimen collection and stabilization market report
Loading Table Of Content...
